Vietnam Accused Of Failing To Follow Law On Drug Import Pricing
This article was originally published in PharmAsia News
Executive SummaryVietnam's regulation of imported drugs is suffering from lax management by the agencies responsible, leading to recent increases in the price of medicine. One of the core problems, according to the Ho Chi Minh City Health Department's deputy director, lies in the Drug Administration of Vietnam's failure to put wholesale and retail prices on its public list. The law requires drug importers to consider the cost, insurance and freight in determining the two types of prices submitted to the DAV. Deputy Director Pham Khanh Phong Lan said the agency lists only the overall CIF prices and does not break out the wholesale and retail prices as required. (Click here for more
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.